FindTrial
Sign In

CDX-1140

DRUG8 trials

Sponsors

Celldex Therapeutics, Craig L Slingluff, Jr, Providence Health & Services, Washington University School of Medicine, University of Texas Southwestern Medical Center

Conditions

Bile Duct CancerBiliary CancerBladder Urothelial CarcinomaBreast CancerCancer of the Bile DuctCancer of the PancreasCholangiocarcinomaColorectal Cancer

Phase 1

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
CompletedNCT03329950
Celldex TherapeuticsBladder Urothelial Carcinoma, Breast Cancer, Cholangiocarcinoma +23
Start: 2017-12-01End: 2022-09-13Updated: 2024-03-28
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
CompletedNCT04364230
Craig L Slingluff, JrMelanoma, Ocular Melanoma, Uveal Melanoma
Start: 2020-09-28End: 2024-03-14Updated: 2024-07-16
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Active, not recruitingNCT04520711
Providence Health & ServicesMalignant Epithelial Neoplasms
Start: 2022-02-08End: 2027-02-28Target: 24Updated: 2025-11-19
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
RecruitingNCT05029999
University of Texas Southwestern Medical CenterHER2-negative Breast Cancer, Metastatic Breast Cancer
Start: 2022-04-20End: 2026-04-20Target: 30Updated: 2025-08-13
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Active, not recruitingNCT05349890
Providence Health & ServicesMalignant Epithelial Neoplasms
Start: 2023-04-03End: 2028-04-15Updated: 2024-11-25
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
TerminatedNCT05484011
HiberCell, Inc.Metastatic Pancreatic Adenocarcinoma
Start: 2022-12-15End: 2024-03-04Updated: 2024-04-10
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
RecruitingNCT05849480
National Cancer Institute (NCI)Bile Duct Cancer, Biliary Cancer, Cancer of the Bile Duct
Start: 2024-05-08End: 2042-06-01Target: 60Updated: 2026-03-24

Phase 2

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
TerminatedNCT04536077
Washington University School of MedicineCancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Start: 2021-08-13End: 2023-11-21Updated: 2024-10-08

Related Papers

Abstract LB-B008: cDC expansion and CD40 activation after immunogenic chemotherapy shift the breast tumor microenvironment toward functional T cell immunity and IL-12-dependent tumor control
Cancer Immunology Research2026-03-05
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).
2026-03-03
Abstract PS5-08-28: Phase I pilot of pegylated liposomal doxorubicin, CD40 agonist antibody CDX-1140, and Flt3 ligand CDX-301 in advanced HER2-negative breast cancer
Clinical Cancer Research2026-02-17
Abstract P3-12-30: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic HER2 negative breast cancer
Clinical Cancer Research2025-06-13
Abstract 6171: Flt3 ligand and CD40 agonist-based therapy in breast cancer promotes myeloid cell CXCL9 secretion and CD8 T cell recruitment but is not dependent on CXCL9 for efficacy
Cancer Research2025-04-21
Abstract PO1-19-08: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer
Cancer Research2024-05-02
Abstract 5314: Improved breast cancer tumor control with addition of CD40 agonist and Flt3 ligand to pegylated liposomal doxorubicin is only partially mediated by CD8 T cells
Cancer Research2024-03-221 citations
Adjuvant polypeptide vaccines for high-risk uveal melanoma.
Journal of Clinical Oncology2023-06-013 citations
Abstract OT2-17-01: Phase 1 trial of anthracycline chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer
Cancer Research2023-03-01
596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
Regular and Young Investigator Award Abstracts2022-11-014 citations
Abstract 4197: Treatment with chemotherapy, CD40 agonist, and Flt3 ligand triplet combination enhances antigen presentation and leads to cures in triple negative breast cancer
Cancer Research2022-06-15
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer.
Journal of Clinical Oncology2022-06-013 citations
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)
Regular and Young Investigator Award Abstracts2020-11-018 citations
Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
Cancer Research2019-07-019 citations
Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
Immunology2019-07-01